Opinion

Video

Evaluating the Benefits of Cretostimogene Plus Pembrolizumab for BCG-Unresponsive NMIBC Management

Panelists discuss how the combination therapy of cretostimogene plus pembrolizumab offers a promising new approach for managing BCG-unresponsive non-muscle-invasive bladder cancer, highlighting its potential benefits and the implications of its FDA Breakthrough Therapy Designation for clinical practice.

Video content above is prompted by the following questions:

  • In your opinion, what does cretostimogene plus pembrolizumab combination therapy offer to the management of BCG-unresponsive NMIBC?
  • Cretostimogene plus pembrolizumab received an FDA Breakthrough Therapy Designation in May 2023. What is important for physicians to know or understand about this designation?
Related Videos
Doctor consulting patient | Image Credit: © Liudmila Dutko - stock.adobe.com
4 experts in this video
4 experts in this video
Female doctor typing on her laptop computer in medical office | Image Credit: © Rostislav Sedlacek - stock.adobe.com
4 experts in this video
4 experts in this video
Rebecca A. Campbell, MD, answers a question during a Zoom video interview
Joshua J. Meeks, MD, PhD, gives an answer during a Zoom video interview
Related Content
© 2025 MJH Life Sciences

All rights reserved.